E
Equity Risk Sciences
Independent stock risk rating agency for fiduciaries
About Equity Risk Sciences
Equity Risk Sciences (ERS) is an independent stock risk rating agency that provides quantitative, evidence-based ratings on the probability and magnitude of stock price changes for institutional investors and financial advisors. The company was formally incorporated in March 2021, but its methodologies have been in development for over a decade.
The company's founder and CEO is Raymond Mullaney, whose career in finance began in 1976. He established a broker-dealer and an SEC-registered investment advisor in 1982. The conceptual work for ERS started in 2013 when Mullaney hired mathematician and data scientist Tom Harpin to develop technology-driven, safer investment strategies. Their goal was to use advanced mathematical modeling on big data to quantify the financial and price risks of individual stocks. ERS positions itself as America's first and only independent stock risk rating agency, emphasizing that it does not manage money, issue recommendations, or receive payments from the companies it rates to ensure objective, conflict-free analysis.
ERS's business model is centered on providing data and risk ratings to fiduciaries to help them meet their legal duty of care by avoiding preventable and catastrophic losses. Revenue is generated through institutional subscriptions, licensing of fiduciary tools like the Fiduciary Approved Stock List™, and premium advisory services. The company's technology utilizes proprietary models powered by SEC-filed financial data and over 35 years of price history. Key products include the Fiduciary Risk Navigator™ (FRN™), which provides a composite rating of a stock's suitability, and the Durability Risk Indicator™ (DRI™), which assesses financial structure and resiliency. In July 2025, the firm announced a $20 million capital raise to fund a national awareness campaign and the rollout of its institutional-grade platform, InvestLabs.ai.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jul 2025 | $20M | $80M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Equity Risk Sciences is 1.7K monthly website visits, up 269.6% over the last three months. Equity Risk Sciences's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
THALEONAI-powered intelligence for modern wealth management. |
Malaysia | Operational | 2 | — | — |
BehindLoginCompetitive intelligence and UX analysis for FinTech. |
United Kingdom | Operational | |||
OmegaFPAI-powered technology stack for financial advisors. |
Phoenix, United States | Operational | |||
AdvizorProB2B contact and intelligence platform for financial services. |
Atlanta, United States | Operational | |||
Signal Market IntelligenceDefensible financial data and AI workflow automation. |
— | Operational | |||
Rahul Rajgopal Wealth AdvisorFee-only, conflict-free wealth advisory for professionals. |
New Delhi, India | Operational | |||
DealTechIQFintech |
New York City, United States | Operational | |||
PenClipPurpose-built CRM for wealth managers and financial advisors. |
Singapore | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Equity Risk Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Equity Risk Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







